Dimensional Fund Advisors LP Grows Stock Position in ICU Medical, Inc. $ICUI

Dimensional Fund Advisors LP lifted its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 6.8% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 983,802 shares of the medical instruments supplier’s stock after purchasing an additional 63,026 shares during the period. Dimensional Fund Advisors LP’s holdings in ICU Medical were worth $127,053,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ICUI. Maryland State Retirement & Pension System grew its position in ICU Medical by 2.0% during the fourth quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier’s stock valued at $516,000 after buying an additional 70 shares during the period. California Public Employees Retirement System raised its position in ICU Medical by 0.3% in the first quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock worth $3,934,000 after acquiring an additional 90 shares during the period. Oregon Public Employees Retirement Fund raised its position in ICU Medical by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock worth $803,000 after acquiring an additional 100 shares during the period. Smartleaf Asset Management LLC boosted its stake in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after acquiring an additional 101 shares during the last quarter. Finally, Lido Advisors LLC boosted its stake in shares of ICU Medical by 4.5% during the 4th quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock worth $354,000 after acquiring an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ICUI shares. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Needham & Company LLC upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research report on Wednesday, May 27th. KeyCorp raised their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 21st. BTIG Research began coverage on ICU Medical in a research report on Monday, June 15th. They set a “buy” rating and a $170.00 price objective on the stock. Finally, Zacks Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $172.00.

Insider Buying and Selling

In other news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the sale, the director owned 7,960 shares in the company, valued at $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total transaction of $303,623.76. Following the completion of the transaction, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.10% of the company’s stock.

ICU Medical Stock Performance

NASDAQ ICUI opened at $161.46 on Tuesday. The firm has a market cap of $4.03 billion, a price-to-earnings ratio of 87.28, a price-to-earnings-growth ratio of 2.20 and a beta of 0.76. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The business has a 50-day moving average price of $144.98 and a 200-day moving average price of $139.78. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $162.85.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The company had revenue of $525.77 million for the quarter, compared to the consensus estimate of $520.65 million. During the same quarter last year, the company earned $1.72 EPS. The firm’s quarterly revenue was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, equities research analysts predict that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.